CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 16 No. 5
Pages: 1  2  3  
Next
Book Review 

The Molecular Basis of Blood Diseases, 3rd Edition

By

Editors: George Stamatoyannopoulos, MD, DRSCI, Philip W. Majerus, MD, Roger M. Perlmutter, MD, PhD, and Harold Varmus, MD
Publisher: W.B. Saunders Company, Philadelphia, 1,028 pages, 465 illustrations, Price: $275.00

Reviewed by:
Martin S. Tallman, MD, Division of Hematology/Oncology, Northwestern University Medical School, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois

| May 1, 2002

This comprehensive text focuses on the pathophysiology of hematologic diseases. There is no field in which molecular techniques have been applied more fruitfully. Given the large amount of rapidly accumulating information in the field, this book fills a niche that will become increasingly important.

Each of the four editors is a distinguished investigator who has made important contributions to our understanding of blood disorders. Dr. George Stamatoyannopoulos is Professor of Medicine in the Division of Medical Genetics at the University of Washington School of Medicine in Seattle; Dr. Philip Majerus is Professor of Medicine and Biological Chemistry in the Division of Hematology/Oncology at the Washington School of Medicine in St. Louis; Dr. Roger Perlmutter is Executive Vice President of Basic Research at Merck Research Laboratories in Rahway, NJ; and Dr. Harold Varmus is President and Chief Executive Officer at Memorial Sloan-Kettering Cancer Center, and Professor of Cell Biology and Genetics at Cornell Medical School in New York. These giants in medicine, in turn, have assembled an outstanding group of contributors.

The book begins with a beautifully written chapter on stem cell biology that carefully describes the organization of hematopoiesis into stem cell compartments. An explanation of the general principles of hematopoietic stem cells, including their properties, identification, and purification, follows. The chapter concludes with a discussion of ex vivo expansion of hematopoietic stem cells, a potentially important strategy in stem cell transplantation.

In the second chapter, Dr. Ken Kaushansky, who has made numerous seminal observations regarding thrombopoiesis, describes hematopoietic growth factors and their receptors. The chapter also reviews the potential role of hematopoietic growth factors in the pathogenesis of various diseases, addressing, for example, the ability of erythropoietin(Drug information on erythropoietin) to stimulate erythropoiesis and improve renal failure. The 5q- syndrome, a well-defined myelodysplastic syndrome, is described. Interestingly, the genes for many hematopoietic growth factors are located on the long-arm of chromosome 5. The role of excessive erythropoietin production in polycythemic states, of mutations in the thrombopoietin gene in patients with familial essential thrombocythemia, and of several cytokines including tumor necrosis factor in the pathogenesis of juvenile chronic myeloid leukemia are also addressed in this chapter.

The third chapter, by Dr. Stuart Orkin from Harvard Medical School, successfully presents the complicated subject of transcription factors so that it is understandable to the non-laboratory-based hematologist or oncologist. The chapter begins with a description of the transcription factors responsible for the development and maintenance of the early progenitors of the hematopoietic stem cell and then discusses the factors responsible for the commitment to myeloid and erythroid lineages. It concludes by addressing the factors responsible for the development of the lymphoid lineage.

As a natural progression, the following chapter by Dr. James Ihle discusses signal transduction as it pertains to hematopoiesis, concluding part I of the book. A large portion of the chapter is devoted to the activation of tyrosine kinase receptors and the consequences of phosphorylation of several substrates. This is particularly important as it provides a background for understanding the mechanism of action of the new bcr-abl tyrosine kinase receptor inhibitor imatinib(Drug information on imatinib) mesylate (Gleevec) in patients with bcr-abl gene rearrangements, such as those with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Part II focuses on red cells and comprises the next six chapters. Chapters 5 through 7 follow in logical sequence and are authored by four individuals (Drs. George Stamatoyannopoulos, Frank Grosveld, D. J. Weatherall, and H. Franklin Bunn) who have made important contributions to our understanding of hemoglobin production and regulation, the thalassemias and other hemoglobinopathies including sickle cell disease. Chapter 5, entitled "Hemoglobin Switching," also makes an otherwise complicated area quite understandable. The next two chapters focus on the erythrocyte, the structure of its membrane, disorders of red cell cytoskeletal proteins, and red cell membrane antigens.

Pages: 1  2  3  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Conflicts of Interest in Medicine: What About Ties to Payers?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy